Coleman RL, Lubinga SJ, Shen Q, Walder L, et al. Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective. Gynecol Oncol 2024;192:24-31.
PMID: 39520771